SUBSEQUENT EVENTS |
12 Months Ended |
|---|---|
Dec. 31, 2022 | |
| Subsequent Events [Abstract] | |
| SUBSEQUENT EVENTS |
NOTE 14—SUBSEQUENT EVENTS Subsequent to December 31, 2022, the Company received net proceeds of $1.0 million in exchange for the issuance of a convertible promissory note in like amount to a related party, $227,000 of net proceeds from related party loans and $500,000 of net proceeds from third party loans. In addition, the Company’s Emmaus Medical, Inc. subsidiary received net proceeds of $984,125 from its sale and assignment to third parties of a total of $1,400,424 of future receipts. The net proceeds from these transactions have been or will be used to augment the Company’s working capital and for general corporate purposes. |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|